The authors then generated dual CAR T-cells targeting MM (via BCMA), as well as CAFs (via either FAP or SLAMF7) and found that both BCMA-FAP and BCMA-SLAMF7 dual targeting CARs were able to overcome CAF-induced CAR T-cell inhibition in an MM-tumor microenvironment (TME) mouse model where the NOD/SCID γ chain-deficient (NSG) mice were simultaneously intravenously injected with both the OPM-2 MM cell line and BM-derived CAFs [148]. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.